Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Articles

Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.

HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.

CVS Caremark Switches Up Biosimilar Coverage in 2024

Videos

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, explains the purpose of dual-pricing strategies for adalimumab biosimilars and predicts whether these strategies will occur in other treatment spaces.

Dr Chelsee Jensen Discusses Pricing Strategies for Adalimumab Biosimilars

A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.

Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Bringing Oncology Biosimilars to Patients

Patient Awareness of Biosimilars and Loyalty to Branded Drugs

Patient Savings From Biosimilars

Barriers to Biosimilars for Oncology Patients

Biosimilars, Payers, and Formulary Changes

The Exceptions Process and its Effect on Patients 

Patient Education on Coverage for Biologics and Biosimilars

Alternative Payment Models and Patient Care

The Cost of Biologics and Biosimilars

Rebates and Medicare Part D

CMS' Changes to Reimbursement for Biosimilars

Biosimilars, Private Payers, and Pharmacy-Level Substitution

Patient Assistance Programs and Biosimilars

Manufacturers and the Cost of Biosimilars and Biologics

Diversity in Clinical Trials for Biosimilars

The FDA and Diversity in Clinical Trials

Oncology Biosimilars Making a Difference for Patients

Putting Patients at the Center of the Biosimilar Conversation